Ibritumomab tiuxetan

Ibritumomab tiuxetan is a targeted cancer treatment for certain types of non-Hodgkin lymphoma. It combines an antibody that specifically targets cancer cells with a radioactive substance, allowing it to deliver radiation directly to tumor sites. This focused approach helps to destroy cancer cells while minimizing damage to healthy tissue. Typically used when other treatments haven't been effective, it’s administered as an intravenous infusion under medical supervision. By precisely attacking cancer cells, ibritumomab tiuxetan can improve treatment outcomes and manage the disease more effectively.